These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21994185)

  • 1. Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
    Darpolor MM; Kennealey PT; Le HC; Zakian KL; Ackerstaff E; Rizwan A; Chen JH; Sambol EB; Schwartz GK; Singer S; Koutcher JA
    NMR Biomed; 2011 Nov; 24(9):1159-68. PubMed ID: 21994185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
    Motwani M; Jung C; Sirotnak FM; She Y; Shah MA; Gonen M; Schwartz GK
    Clin Cancer Res; 2001 Dec; 7(12):4209-19. PubMed ID: 11751522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
    Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
    Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
    Song Y; Shen K; Tang PP
    Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
    Ambrosini G; Seelman SL; Qin LX; Schwartz GK
    Cancer Res; 2008 Apr; 68(7):2312-20. PubMed ID: 18381438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
    Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
    Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
    Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.
    Arguello F; Alexander M; Sterry JA; Tudor G; Smith EM; Kalavar NT; Greene JF; Koss W; Morgan CD; Stinson SF; Siford TJ; Alvord WG; Klabansky RL; Sausville EA
    Blood; 1998 Apr; 91(7):2482-90. PubMed ID: 9516149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
    Shah MA; Kortmansky J; Motwani M; Drobnjak M; Gonen M; Yi S; Weyerbacher A; Cordon-Cardo C; Lefkowitz R; Brenner B; O'Reilly E; Saltz L; Tong W; Kelsen DP; Schwartz GK
    Clin Cancer Res; 2005 May; 11(10):3836-45. PubMed ID: 15897584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
    Motwani M; Sirotnak FM; She Y; Commes T; Schwartz GK
    Cancer Res; 2002 Jul; 62(14):3950-5. PubMed ID: 12124325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
    Shapiro GI
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Synergism of antitumor effects on ovarian carcinoma using autocatalytic caspase-3 combined with flavopiridol].
    Song Y; Shen K; Xu F
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):781-6. PubMed ID: 21176562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
    Raju U; Nakata E; Mason KA; Ang KK; Milas L
    Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
    Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells.
    Motwani M; Rizzo C; Sirotnak F; She Y; Schwartz GK
    Mol Cancer Ther; 2003 Jun; 2(6):549-55. PubMed ID: 12813134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
    Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
    Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
    Dickson MA; Shah MA; Rathkopf D; Tse A; Carvajal RD; Wu N; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1113-21. PubMed ID: 20953860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
    Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
    Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.
    Muruganandham M; Alfieri AA; Matei C; Chen Y; Sukenick G; Schemainda I; Hasmann M; Saltz LB; Koutcher JA
    Clin Cancer Res; 2005 May; 11(9):3503-13. PubMed ID: 15867253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.